Pulmotil G100 Premix for Medicated Feedingstuff

国家: 英国

语言: 英文

来源: VMD (Veterinary Medicines Directorate)

有效成分:

Tilmicosin

可用日期:

Eli Lilly and Company Limited

ATC代码:

QJ01FA91

INN（国际名称）:

Tilmicosin

药物剂型:

Premix for medicated feeding stuff

处方类型:

POM-V - Prescription Only Medicine – Veterinarian

治疗组:

Pigs, Rabbits

治疗领域:

Antimicrobial

授权状态:

Authorized

授权日期:

1995-11-17

产品特点

AN: 00506/2013
Revised: October 2013
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Pulmotil G100 Premix for Medicated Feedingstuff
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE SUBSTANCE:
Tilmicosin (as phosphate)
100 g/kg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Premix for medicated feeding stuff.
A yellowish tan to reddish tan free-flowing granular material.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Pigs and rabbits.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Pigs: Prevention and treatment of respiratory disease caused by
_Actinobacillus _
_pleuropneumoniae,_
_ _
_Mycoplasma _
_hyopneumoniae,_
_Pasteurella multocida_ and other organisms sensitive to tilmicosin.
Rabbits: Prevention and treatment of respiratory disease caused by
_Pasteurella multocida_ and
_Bordetella bronchiseptica_, susceptible to tilmicosin.
4.3
CONTRAINDICATIONS
Horses or other Equidae, must not be allowed access to feeds
containing tilmicosin. Horses fed with tilmicosin medicated feeds may
present signs of toxicity with lethargy, anorexia, reduction of feed
consumption, loose stools, colic, distension of the abdomen and death.
Do not use in case of hypersensitivity to tilmicosin or to any of the
excipients
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Under practical conditions, the management of respiratory disease
outbreaks recognises that acutely ill animals are inappetant and
require
parenteral therapy.
Page 1 of 7
AN: 00506/2013
Revised: October 2013
4.5
SPECIAL PRECAUTIONS FOR USE
i)
Special precautions for use in animals
Inappropriate use of the product may increase the prevalence of
bacteria resistant to tilmicosin and may decrease the effectiveness of
treatment with tilmicosin related substances.
Official, national and regional antimicrobial policies should be taken
into
account when the product is used.
Due to the likely variability (time, geographical) in the occurrence
of the
resistance of bacteria for
tilmicosin, bacteriological
sampling and suscepti